Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

American Journal of Gastroenterology

Volumn 103, Issue 6, 2008, Pages 1372-1379

  Wieckowska, Anna ^a   Papouchado, Bettina G ^a   Li, ZhengZheng ^a   Lopez, Rocio ^a   Zein, Nizar N ^a   Feldstein, Ariel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LONG CHAIN FATTY ACID; MESSENGER RNA;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEATOSIS; UPREGULATION;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 44949233003     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01774.x     Document Type: Article

References (34)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003 289 : 76 9.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002 346 : 1221 31.
3. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: A review. Curr Opin Pediatr 2005 17 : 636 41.
4. Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005 10 : 1475 84.
5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 9.
6. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004 8 : 521 33.
7. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004 8 : 575 94.
8. Diehl AM, Clarke J, Brancati F. Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr Pract 2003 9 (Suppl 2 93 6.
9. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004 19 : 854 8.
10. Adams LA, Harmsen WS, St Sauver JL, et al. Nonalcoholic fatty liver disease is a risk factor for overall mortality among patients with diabetes: A population based study. Hepatology 2005 42 : 614A.
11. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005 129 : 113 21.
12. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005 41 : 64 71.
13. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005 11 : 183 90.
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 21.
15. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006 44 : 874 80.
16. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 125 : 437 43.
17. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 1998 101 : 1343 52.
18. Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas-mediated liver injury in mice. J Hepatol 2003 39 : 978 83.
19. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004 40 : 185 94.
20. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002 2 : 210 5.
21. Lagathu C, Bastard JP, Auclair M, et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochem Biophys Res Commun 2003 311 : 372 9.
22. Klover PJ, Zimmers TA, Koniaris LG, et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003 52 : 2784 9.
23. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 : 327 34.
24. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003 38 : 413 9.
25. Hill DB, Marsano L, Cohen D, et al. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992 119 : 547 52.
26. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006 44 : 1167 74.
27. Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005 54 : 303 6.
28. El-Assal O, Hong F, Kim WH, et al. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004 1 : 205 11.
29. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996 274 : 1379 83.
30. Blindenbacher A, Wang X, Langer I, et al. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003 38 : 674 82.
31. Jin X, Zimmers TA, Perez EA, et al. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006 43 : 474 84.
32. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells. Hepatology 2006 44 : 1487 501.
33. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997 82 : 4196 200.
34. Jung BD, Kimura K, Kitamura H, et al. Norepinephrine stimulates interleukin-6 mRNA expression in primary cultured rat hepatocytes. J Biochem (Tokyo) 2000 127 : 205 9.